Chronic Leukemia — Trials

Chronic Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

1,705 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 411
Recruiting: 207
Ph III recruiting: 22
Growth YoY: −13.3%
Industry share: 28%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 32.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (302)

clinicaltrialsPublishedShowing 101–127 of 127 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00391066	Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)(LUCID)	terminated	Phase 2	627	BiogenINDUSTRY	23	Oct 2, 2015	clinicaltrials
NCT00801060	Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)	terminated	Phase 2	40	BiogenINDUSTRY	8	Oct 2, 2015